10 completed, 1 active not recruiting, 1 enrolling by invitation, 1 recruiting. 14 Phase 2, 4 Phase 3, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 14 | Completed 10, Active not recruiting 1, Enrolling by invitation 1, Recruiting 1, Unknown 1 |
| Phase 3 | 4 | Completed 3, Recruiting 1 |
| Phase 1 | 1 | Unknown 1 |
Follow Prurigo Nodularis: new trials by email Literature Review of Prurigo Nodularis trials Research Report on Prurigo Nodularis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy of Topical Cannabidiol for Eczema Cannabidiol (CBD), Triamcinolone (TAC) 0.1% cream - Chronic Pruritus, Eczema | Phase 2 | Enrolling by invitation | Khon Kaen University | 60 | 2025-05-01 | 2026-08-04 |
| Clinical Study of the Efficacy and Safety of SHR-1819 Injection in Adult Patients With Prurigo Nodularis SHR-1819 Injection, SHR-1819 Injection Placebo - Prurigo Nodularis | Phase 2 / Phase 3 | Recruiting | Guangdong Hengrui Pharmaceutical Co., Ltd | 423 | 2024-09-19 | 2026-04-29 |
| A Study of Barzolvolimab in Patients With Prurigo Nodularis barzolvolimab, Matching Placebo - Prurigo Nodularis | Phase 2 | Active not recruiting | Celldex Therapeutics | 140 | 2024-04-12 | 2026-08-04 |
| A Study to Evaluate the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis INCB054707, Placebo - Prurigo Nodularis | Phase 2 | Completed | Incyte Corporation | 146 | 2021-11-04 | 2025-07-11 |
| Efficacy of Abrocitinib for Reducing Pruritus in Adults With Prurigo Nodularis and Chronic Pruritus of Unknown Origin Abrocitinib - Prurigo Nodularis, Pruritus | Phase 2 | Completed | Johns Hopkins University | 20 | 2021-09-09 | 2023-07-03 |
| Study to Assess the Efficacy, Safety, and Tolerability of Vixarelimab in Reducing Pruritus in Prurigo Nodularis Vixarelimab, Placebo - Prurigo Nodularis, Pruritis | Phase 2 | Completed | Genentech, Inc. | 240 | 2019-03-11 | 2026-01-13 |
| PRISM Study-Pruritus Relief Through Itch Scratch Modulation Nalbuphine ER Tablets, Placebo Tablets - Prurigo Nodularis | Phase 2 / Phase 3 | Completed | Trevi Therapeutics | 353 | 2018-08-07 | 2025-06-24 |
| Safety and Efficacy of Nemolizumab in PN CD14152 Dose A, CD14152 placebo - Prurigo Nodularis | Phase 2 | Completed | Galderma R&D | 70 | 2017-10-02 | 2020-02-19 |
| Apremilast as Anti-pruritic Treatment in Patients With Prurigo Nodularis Apremilast Oral Product - Prurigo Nodularis | Phase 1 / Phase 2 | Unknown | Tanja Todberg, MD | 15 | 2017-07-01 | 2018-07-03 |
| Open Label Extension Study of Nalbuphine HCl ER in Patients With Prurigo Nodularis nalbuphine HCl ER - Prurigo Nodularis, Nodularis Prurigo | Phase 2 / Phase 3 | Completed | Trevi Therapeutics | 36 | 2015-08-15 | 2025-05-21 |
| Study of Nalbuphine HCl ER Tablets in Patients With Prurigo Nodularis nalbuphine HCl ER tablets 90 mg BID, nalbuphine HCl ER tablets 180 mg BID, Placebo tablets BID - Prurigo Nodularis, Nodularis Prurigo | Phase 2 / Phase 3 | Completed | Trevi Therapeutics | 62 | 2015-03-01 | 2025-05-21 |
| A Randomized Placebo-Controlled Study of the Neurokinin-1 (NK1) Receptor Antagonist Serlopitant Prurigo Nodularis (PN) serlopitant, Placebo - Prurigo Nodularis | Phase 2 | Completed | Vyne Therapeutics Inc. | 128 | 2014-07-09 | 2021-05-20 |
| Safety and Efficacy of CC-10004 for Prurigo Nodularis CC-10004 - Prurigo Nodularis | Phase 2 | Completed | University Hospitals Cleveland Medical Center | 5 | 2008-09-01 | 2016-11-02 |
| Evaluation of the Antipruritic Effect of Elidel (Pimecrolimus) in Non-atopic Pruritic Disease Pimecrolimus, Hydrocortisone - Prurigo Nodularis | Phase 2 | Completed | University Hospital Muenster | 30 | 2007-04-01 | 2010-07-07 |
Pruritus (4) · Dermatitis, Atopic (2) · Prurigo (2) · Eczema (1) · Lichenoid Eruptions (1) · Skin Diseases (1)
Skin and Connective Tissue Diseases (6) · Skin Diseases (5) · Pathological Conditions, Signs and Symptoms (4) · Signs and Symptoms (4) · Skin Manifestations (4) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (2) · Dermatitis (2) · Genetic Diseases, Inborn (2) · Hypersensitivity (2) · Hypersensitivity, Immediate (2) · Immune System Diseases (2) · Skin Diseases, Eczematous (2) · Skin Diseases, Genetic (2) · Skin Diseases, Papulosquamous (1)
BID protein, human (1) · Cannabidiol (1) · Hydrocortisone (1) · Nalbuphine (1) · Sugars (1) · Triamcinolone (1) · abrocitinib (1) · apremilast (1) · nemolizumab (1) · pimecrolimus (1) · serlopitant (1)
Trevi Therapeutics (3) · Celldex Therapeutics (1) · Galderma R&D (1) · Genentech, Inc. (1) · Guangdong Hengrui Pharmaceutical Co., Ltd (1) · Incyte Corporation (1) · Johns Hopkins University (1) · Khon Kaen University (1) · Tanja Todberg, MD (1) · University Hospital Muenster (1) · University Hospitals Cleveland Medical Center (1) · Vyne Therapeutics Inc. (1)
Germany (9) · United States (7) · Poland (6) · Austria (3) · Canada (3) · France (3) · Spain (2) · Australia (1) · Belgium (1) · China (1) · Croatia (1) · Czechia (1) · Denmark (1) · Italy (1) · Puerto Rico (1)
Kathleen Butler, MD (1) · Neil Korman, M.D.,PhD. (1) · Shawn G Kwatra, MD (1) · Sonja Staender, MD (1) · Thomas A Luger, MD (1)
PMID 32074418, PMID 32936233, PMID 34780095, PMID 34908192, PMID 36680419, PMID 36816342, PMID 37615836, PMID 38837144, PMID 41051123, PMID 41405882
2016 (1), 2018 (1), 2023 (1)